Aura Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $90.3M | $73.3M | $65.2M | $42.2M | $25.2M | $18.0M |
| SG&A Expense | — | $22.5M | $22.8M | $19.8M | $18.1M | $10.1M | $4.2M |
| Operating Income | — | $-112.8M | $-96.1M | $-85.0M | $-60.3M | $-35.3M | $-22.2M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | $-106.1M | $-86.8M | $-76.3M | $-58.8M | — | — |
| Income Tax Expense | — | $108.0K | $112.0K | $137.0K | $0 | $0 | $0 |
| Net Income | — | $-106.2M | $-86.9M | $-76.4M | $-58.8M | $-35.3M | $-22.2M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-1.49 | $-13.68 |
| EPS (Diluted) | — | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-1.49 | $-13.68 |
| Shares Outstanding (Basic) | 64.2M | 60.3M | 49.7M | 39.6M | 29.9M | 31.0M | 2.3M |
| Shares Outstanding (Diluted) | 64.2M | 60.3M | 49.7M | 39.6M | 29.9M | 31.0M | 2.3M |
| Dividends Per Share | — | — | — | — | — | — | — |